Recently, Sansure Biotech Inc.'s new product launch conference and business partner recruitment conference was held in Changsha, China. More than 1,500 people participated in the conference and more than 120 dealers signed agreement.

A key meeting of the Communist Party of China unveiled on the last day of May a policy that would allow all couples to have up to three children, in place of the current universal two-child policy, in a bid to cope with an increasingly aging society.

June 1st, WHO validated the Sinovac-CoronaVac COVID-19 vaccine for emergency use, which is produced by the Beijing-based pharmaceutical company Sinovac.

On May 31, 2021, Reliable Medical Technology CO., Ltd. (hereinafter referred to as "Reliable Med") issued an announcement announcing that the company had recently completed A+ round of financing of tens of millions of yuan.

On May 28, the website of the Chinese Center for Disease Control and Prevention published the "General Information on Adverse Reaction Monitoring of COVID-19 Vaccine Vaccination" jointly published by the center and the National Adverse Drug Reaction Monitoring Center.

The average annual growth rate from 2010 to 2020 is 0.53%, which is 0.04 percentage points lower than the 0.57% in 2000-2010.

On the evening of May 25, China Securities Regulatory Commission (CSRC) announced that the listing committee of science and technology innovation board approved the IPO application of Vazyme Biotech Co., Ltd.

China has worked together with other countries in the world to overcome difficulties and contribute wisdom and strength to the global epidemic.

On May 12th, Sansure Biotech Inc. issued an announcement that Sansure Biotech will purchase 95,863,038 shares of Shanghai Kehua Bio-Engineering Co., Ltd. (accounting for 18.63% of Kehua's total share capital) held by Gree DC through agreement.

On May 17, 2021, Shenzhen YHLO Biotech Co., Ltd. was listed on the Science and Technology Innovation Board of the Shanghai Stock Exchange.

On May 16, Mindray Medical announced that it intends to acquire 100% of the equity of HytestInvest Oy in Finland and its subsidiaries.

The COVID-19 mRNA vaccine co-developed by German-based BioNTech and China's Fosun Pharma can be rolled out in the Chinese mainland very quickly once it receives authorization, as key steps for mass production are close to ready.

On May 11, BioPerfectus officially announced that their COVID-19 test kit for B.1.617 has been successfully developed.

On May 10th , BGI announced that NUPCO of the Kingdom of Saudi Arabia had recently added a further $38,176,076 to the contract.

On May 10, 2021, Hong Tan, CEO of ET Healthcare, announced that Access Medical Systems (AMS), the parent company of ET Healthcare, has closed a new round of financing in a deal worth more than $100 million.